\u3cem\u3e Swietenia mahagoni \u3c/em\u3e Leaves Extract: Antifungal, Insecticidal, and Phytochemical Analysis

In this study, we investigated the antifungal properties of an acetone extract derived from the leaves of Swietenia mahagoni (SMAL) against two isolated fungi, Fusarium equiseti (OQ820153) and Rhizoctonia solani (OQ820152), from rice sheath. The extract was effective in inhibiting the growth of both fungi at the highest concentration tested, 3000 μg·mL−1. Laboratory tests on the LC20 of SMAL extract (49.86 mg·L−1) versus pyriproxyfen 10% EC (1.96 mg·L−1) were accomplished on Aphis gossypii Glover. The extract potently reduced the survival of the nymphs (49.58%) more than the other treatments. The longevity of nymphs treated with the extract had the highest prolongation at 9.67 days. The olfactory choice test exhibited the lowest aphid attraction percentage (23.33%). The HPLC of SMAL extract contained various phenolic compounds, and the most abundant found were catechin (752.64 µg·g−1), gallic acid, and chlorogenic acid, as well as flavonoids such as rutin (585.24 µg·g−1) and naringenin. A GC–MS analysis revealed n-hexadecanoic acid (37.1%) as the major compound, followed by oleic acid. These results suggest that SMAL extract has the potential to help plants fight against fungal and insect infections, making it a promising natural and renewable solution for long-term plant pest regulation

Appraising the role of anti-thermal activity of beta-cyclodextrin on selective insecticides against Thrips tabaci (Thysanoptera: Thripidae)

Abstract Evaluation studies investigated the leverage effects of beta-cyclodextrin (β-CD) on the long-termed toxicity of cypermethrin 25% EC, sulfoxaflor 24% SC, acetamiprid 20% SL and chlorfenapyr 24% SC against adults of Thrips tabaci laboratory strain (Thysanoptera: Thripidae) (Lindeman, 1889) from 8 up to 40 °C. Laboratory studies showed no toxicity for β-CD alone at all tested concentrations. Concentrations of β-CD at 1.25 and 2.50 gm L−1 had potent leverage effects on the LC50s of cypermethrin within 30–35 °C and sulfuxoflor at 40 °C. β-CD at 0.5 gm L−1 had no leverage effect on tested insecticides. All the tested concentrations of β-CD decreased the toxicity of acetamiprid. Semi-field trials (≥28 °C) along 12 days declared that β-CD (equivalent to 1.25 gm L−1) increased the overall mean mortality percentages of 0.5 FRs of cypermethrin (73.08%) and sulfoxaflor (54.74%) compared to their 0.5 FRs alone of 63.70 and 44.30%, respectively in season 2020. While in season 2021, only cypermethrin at 0.5 FR + β-CD (74.45%) surpassed its 0.5FR (61.83%). Lethal times (LT50) values in semi-field trials showed a prolonged residual toxicity periods for the 0.5 FRs of cypermethrin + β-CD (8.58 days) and sulfoxaflor + β-CD (4.80 days) compared to their 0.5 FRs of 6.65 and 3.24 days, respectively in season, 2020. Furthermore, LT50 values of the 0.5 FRs of cypermethrin + β-CD (9.02 days) and sulfoxaflor + β-CD (7.34 days) exceeded their 0.5 FRs of 6.24 and 4.07 days, respectively in 2021. Thus β-CD could realize leverage efficacy and longer-termed toxicity for cypermethrin and sulfoxaflor in high temperatures

The strategic plan for combating antimicrobial resistance in Gulf Cooperation Council States

Summary: The Gulf Cooperation Council Center for Infection Control (GCC-IC) has placed the emergence of antimicrobial resistance (AMR) on the top of its agenda for the past four years. The board members have developed the initial draft for the GCC strategic plan for combating AMR in 2014. The strategic plan stems from the WHO mandate to combat AMR at all levels. The need for engaging a large number of stakeholders has prompted the GCC-IC to engage a wider core of professionals in finalizing the plan. A multi-disciplinary group of more than 40 experts were then identified. And a workshop was conducted in Riyadh January 2015 and included, for the first time, representation of relevant ministries and agencies as well as international experts in the field. Participants worked over a period of two and a half days in different groups. International experts shared the global experiences and challenges in addressing human, food, animal, and environmental aspects of controlling AMR. Participants were then divided into 4 groups each to address the human, animal, microbiological and diagnostic, or the environmental aspect of AMR. At the end of the workshop, the strategic plan was revised and endorsed by all participants. The GCC-IC board members then approved it as the strategic plan for AMR. The document produced here is the first GCC strategic plan addressing AMR, which shall be adopted by GCC countries to develop country-based plans and related key performance indicators (KPIs). It is now the role of each country to identify the body that will be accountable for implementing the plan at the country level. Keywords: Strategic plan, Antimicrobial resistance, AMR, GCC, Saudi Arabia, United Arab Emirates, Qatar, Bahrain, Oman, Kuwai

International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module

•We report INICC device-associated module data of 50 countries from 2010-2015.•We collected prospective data from 861,284 patients in 703 ICUs for 3,506,562 days.•DA-HAI rates and bacterial resistance were higher in the INICC ICUs than in CDC-NHSN's.•Device utilization ratio in the INICC ICUs was similar to CDC-NHSN's. Background: We report the results of International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2010-December 2015 in 703 intensive care units (ICUs) in Latin America, Europe, Eastern Mediterranean, Southeast Asia, and Western Pacific. Methods: During the 6-year study period, using Centers for Disease Control and Prevention National Healthcare Safety Network (CDC-NHSN) definitions for device-associated health care-associated infection (DA-HAI), we collected prospective data from 861,284 patients hospitalized in INICC hospital ICUs for an aggregate of 3,506,562 days. Results: Although device use in INICC ICUs was similar to that reported from CDC-NHSN ICUs, DA-HAI rates were higher in the INICC ICUs: in the INICC medical-surgical ICUs, the pooled rate of central line-associated bloodstream infection, 4.1 per 1,000 central line-days, was nearly 5-fold higher than the 0.8 per 1,000 central line-days reported from comparable US ICUs, the overall rate of ventilator-associated pneumonia was also higher, 13.1 versus 0.9 per 1,000 ventilator-days, as was the rate of catheter-associated urinary tract infection, 5.07 versus 1.7 per 1,000 catheter-days. From blood cultures samples, frequencies of resistance of Pseudomonas isolates to amikacin (29.87% vs 10%) and to imipenem (44.3% vs 26.1%), and of Klebsiella pneumoniae isolates to ceftazidime (73.2% vs 28.8%) and to imipenem (43.27% vs 12.8%) were also higher in the INICC ICUs compared with CDC-NHSN ICUs. Conclusions: Although DA-HAIs in INICC ICU patients continue to be higher than the rates reported in CDC-NSHN ICUs representing the developed world, we have observed a significant trend toward the reduction of DA-HAI rates in INICC ICUs as shown in each international report. It is INICC's main goal to continue facilitating education, training, and basic and cost-effective tools and resources, such as standardized forms and an online platform, to tackle this problem effectively and systematically